Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia

Rhea-AI Summary

Nabriva Therapeutics (NASDAQ: NBRV) has announced that its partner, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., received approval to market oral and IV formulations of XENLETA (lefamulin) for treating community-acquired pneumonia (CAP) in adults in Taiwan. This follows Nabriva's agreement with Sumitomo in May 2021 for the commercialization rights of lefamulin in the greater China region. The launch date for XENLETA in Taiwan has not yet been determined.

Positive

• Approval for XENLETA in Taiwan expands market potential.
• XENLETA is positioned as a treatment for a significant health issue, community-acquired pneumonia.

Negative

• Launch timing of XENLETA in Taiwan remains uncertain, which may delay revenue impact.

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. has received approval to market oral and intravenous (IV) formulations of XENLETA^® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults in Taiwan.

In May 2021, Nabriva entered into an agreement for the development and commercialization rights for lefamulin in the greater China Region to Sumitomo Pharmaceuticals (Suzhou), the Chinese affiliate of Sumitomo Dainippon Pharma. The anticipated launch timing of XENLETA^® in Taiwan is undecided.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA^® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO^® (tedizolid phosphate) in the United States and certain of its territories.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about the ability of Nabriva Therapeutics to raise awareness of XENLETA and SIVEXTRO and drive top-line sales growth, the potential benefits to patients of SIVEXTRO and XENLETA, the market opportunity for SIVEXTRO and XENLETA, the availability of SIVEXTRO through major U.S. specialty wholesalers, the impact on Nabriva Therapeutics’ reported revenue from anticipated sales of SIVEXTRO, the sufficiency of its cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics' ability to comply with its obligations under its loan agreement with Hercules, Nabriva Therapeutics' ability to maintain the conditions under the distribution agreement to exclusively distribute and promote SIVEXTRO, including its ability to maintain a commercial infrastructure sufficient to promote and distribute SIVEXTRO, the extent of business interruptions resulting from the infection causing the COVID-19 outbreak or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the SEC. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments may cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.

CONTACTS:

For Investors

Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com

For Media

Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027

FAQ

What recent approval did Nabriva Therapeutics announce regarding NBRV?

Nabriva Therapeutics announced that its partner received approval to market XENLETA in Taiwan.

What is <b>XENLETA</b> used for?

XENLETA is used for the treatment of community-acquired pneumonia in adults.

When is <b>XENLETA</b> expected to launch in Taiwan?

The launch timing for XENLETA in Taiwan is currently undecided.

What partnership is involved in the commercialization of <b>XENLETA</b>?

Nabriva entered a partnership with Sumitomo Pharmaceuticals (Suzhou) for the commercialization of XENLETA in the greater China region.